The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A 17alpha-hydroxy-C21-steroid that is pregn-4-ene substituted by oxo groups at positions 3 and 20 and hydroxy groups at positions 11, 17 and 21. Cortisol is a corticosteroid hormone or glucocorticoid produced by zona fasciculata of the adrenal cortex, which is a part of the adrenal gland. It is usually referred to as the 'stress hormone' as it is involved in response to stress and anxiety, controlled by corticotropin-releasing hormone (CRH). It increases blood pressure and blood sugar, and reduces immune responses.
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of A2M mRNA
Elacridar inhibits the reaction [ABCB1 protein results in increased secretion of Hydrocortisone]; valspodar inhibits the reaction [ABCB1 protein results in increased secretion of Hydrocortisone]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ABCC1 mRNA
Hydrocortisone promotes the reaction [ABCC3 protein affects the transport of calcein AM] Hydrocortisone results in increased expression of ABCC3 mRNA Hydrocortisone results in increased activity of ABCC3 protein
Hydrocortisone results in increased expression of ACACA mRNA [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ACSL5 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ACTN2 mRNA
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of AFP mRNA
AKR1D1 protein results in increased reduction of Hydrocortisone AKR1D1 protein alternative form results in increased reduction of Hydrocortisone; AKR1D1 protein results in increased reduction of Hydrocortisone [AKR1D1 protein alternative form results in increased reduction of Hydrocortisone] which results in increased chemical synthesis of 5-dihydrocortisol
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALB mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALDOA mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of AMHR2 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ANXA1 mRNA; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of ANXA1 mRNA]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of APOA1 mRNA
IGF1 protein inhibits the reaction [Hydrocortisone results in decreased expression of APOB mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of APOB mRNA]
Hydrocortisone affects the activity of AR protein Hydrocortisone binds to AR protein Hydrocortisone binds to AR protein mutant form Hydrocortisone binds to and results in increased activity of AR protein; Hydrocortisone binds to and results in increased activity of AR protein mutant form
Hydrocortisone results in increased expression of ARG1 mRNA Methoxychlor inhibits the reaction [Hydrocortisone results in increased expression of ARG1 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of ARG1 mRNA]; o,p'-DDT inhibits the reaction [Hydrocortisone results in increased expression of ARG1 mRNA]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ASCL1 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of BMP5 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CAMK2B mRNA
Hydrocortisone results in increased activity of CASP3 protein Hydrocortisone inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]
Hydrocortisone results in decreased expression of CCL2 protein Hydrocortisone inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CDC20 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CDH10 mRNA
Hydrocortisone results in increased localization of CDH5 protein GGTI 298 inhibits the reaction [Hydrocortisone results in increased localization of CDH5 protein]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CEACAM6 mRNA
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; CEBPA protein affects the reaction [Hydrocortisone results in increased expression of FASN mRNA]; CEBPA protein affects the reaction [Hydrocortisone results in increased expression of SREBF1 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of CEBPA mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein] Hydrocortisone results in increased expression of CEBPA mRNA; Hydrocortisone results in increased expression of CEBPA protein
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CIDEC mRNA
Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of COL1A1 mRNA]; Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of COL1A1 protein]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of COL3A1 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CRYAB mRNA
Hydrocortisone results in decreased activity of CS protein Dactinomycin inhibits the reaction [Hydrocortisone results in decreased activity of CS protein]
Hydrocortisone results in decreased secretion of CSF2 protein Glycyrrhetinic Acid promotes the reaction [Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]]; Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]
Hydrocortisone results in increased localization of CTNNB1 protein GGTI 298 inhibits the reaction [Hydrocortisone results in increased localization of CTNNB1 protein]
Hydrocortisone results in decreased expression of CYP11A1 mRNA; Hydrocortisone results in decreased expression of CYP11A1 protein HDAC1 protein affects the reaction [Hydrocortisone results in decreased expression of CYP11A1 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of CYP11A1 mRNA] Hydrocortisone affects the expression of CYP11A1 mRNA
CYP11B1 protein results in increased chemical synthesis of Hydrocortisone 3',4'-dimethoxyflavone promotes the reaction [CYP11B1 protein results in increased chemical synthesis of Hydrocortisone]; alpha-naphthoflavone promotes the reaction [CYP11B1 protein results in increased chemical synthesis of Hydrocortisone]; beta-Naphthoflavone promotes the reaction [CYP11B1 protein results in increased chemical synthesis of Hydrocortisone] CYP11B1 protein affects the metabolism of Hydrocortisone
[Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 protein]
[Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 protein]; Hydrocortisone inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 mRNA]; Hydrocortisone inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 protein] Hydrocortisone results in decreased expression of CYP1B1 protein
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP24A1 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP26B1 mRNA
Hydrocortisone results in increased expression of CYP3A2 mRNA CYP3A4 protein affects the metabolism of Hydrocortisone CYP3A4 promoter mutant form inhibits the reaction [Hydrocortisone results in increased expression of CYP3A4 mRNA]; kaempferol inhibits the reaction [CYP3A4 protein results in increased degradation of Hydrocortisone]; Quercetin inhibits the reaction [CYP3A4 protein results in increased degradation of Hydrocortisone] CYP3A4 protein affects the hydroxylation of Hydrocortisone CYP3A4 protein results in increased metabolism of Hydrocortisone
Hydrocortisone results in increased expression of CYP3A5 mRNA [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP3A5 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCC mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCN mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCX mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DHRS9 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DNAJB1 mRNA
Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA]; Hydrocortisone inhibits the reaction [[sodium arsenite results in increased abundance of arsenite] which results in decreased expression of DSG1 mRNA]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF1 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF3 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ECSCR mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]]; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ABCC1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ACTN2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of AFP mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALDOA mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of APOA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CDC20 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CIDEC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CRYAB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ECSCR mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of EGLN3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ESRG mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FGB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FLT1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXD3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXG1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GCLC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GPX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of H2BC14 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HES5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HMOX1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of LCK mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MAFG mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MMP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MYL4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of NQO1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of PLN mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of POU5F1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SCARB1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SERPINA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SFRP2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SPTSSB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SRXN1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TM4SF4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TTR mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of UGT2A3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of A2M mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ACSL5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of AMHR2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ANXA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ASCL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of BMP5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CAMK2B mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CDH10 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CEACAM6 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of COL3A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP24A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP26B1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP3A5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCN mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCX mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DHRS9 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DNAJB1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EMX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FABP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FAH mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FBXO32 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FGF7 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FLRT3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GADD45A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GATA6 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GCLM mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GPR183 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GSTO1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GUCY1A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAND2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAVCR1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXB3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD8 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IFI44 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IGFBP7 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IGHV3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IL1R1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ISL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of KEAP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of KRT6A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LEF1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LUM mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MLIP mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MPZL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of PDE1A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RARA mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RBM20 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RRAD mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SEMA3C mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SH3BP5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SQSTM1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of STMN2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TBX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TF mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2B mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TXNRD1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VCAM1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VGLL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ZFAND2A mRNA; Gefitinib promotes the reaction [Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]]; Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]; Hydrocortisone inhibits the reaction [EGF protein results in increased expression of PTGS2 mRNA]; Indomethacin promotes the reaction [Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of EGLN3 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL3 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL4 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EMX2 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FABP1 mRNA
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FAH mRNA
[HIV Envelope Protein gp120 co-treated with Hydrocortisone] results in increased expression of FAS mRNA; Hydrocortisone promotes the reaction [Mitoxantrone results in increased expression of FAS] Hydrocortisone results in increased expression of FAS protein
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; CEBPA protein affects the reaction [Hydrocortisone results in increased expression of FASN mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Resveratrol inhibits the reaction [Hydrocortisone results in increased expression of FASN mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FBXO32 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FGB mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FGF7 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ABCC1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ACTN2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of AFP mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALDOA mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of APOA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CDC20 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CIDEC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CRYAB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ECSCR mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of EGLN3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ESRG mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FGB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FLT1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXD3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXG1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GCLC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GPX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of H2BC14 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HES5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HMOX1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of LCK mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MAFG mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MMP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MYL4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of NQO1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of PLN mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of POU5F1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SCARB1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SERPINA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SFRP2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SPTSSB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SRXN1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TM4SF4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TTR mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of UGT2A3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of A2M mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ACSL5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of AMHR2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ANXA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ASCL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of BMP5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CAMK2B mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CDH10 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CEACAM6 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of COL3A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP24A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP26B1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP3A5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCN mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCX mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DHRS9 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DNAJB1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EMX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FABP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FAH mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FBXO32 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FGF7 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FLRT3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GADD45A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GATA6 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GCLM mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GPR183 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GSTO1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GUCY1A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAND2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAVCR1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXB3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD8 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IFI44 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IGFBP7 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IGHV3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IL1R1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ISL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of KEAP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of KRT6A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LEF1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LUM mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MLIP mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MPZL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of PDE1A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RARA mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RBM20 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RRAD mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SEMA3C mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SH3BP5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SQSTM1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of STMN2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TBX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TF mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2B mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TXNRD1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VCAM1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VGLL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ZFAND2A mRNA
Hydrocortisone results in decreased expression of FLG mRNA Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FLRT3 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FLT1 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXD3 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXG1 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GADD45A mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GATA6 mRNA
Hydrocortisone results in increased expression of GCLC mRNA [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GCLC mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GCLM mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GPR183 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GPX2 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA2 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA3 mRNA
Hydrocortisone results in increased expression of GSTA1 mRNA [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA1 mRNA; Hydrocortisone results in increased expression of and results in increased activity of GSTA1 protein
Hydrocortisone inhibits the reaction [sulforaphane results in increased expression of GSTA2 mRNA] [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA2 mRNA Hydrocortisone results in decreased expression of GSTA2 mRNA Hydrocortisone results in increased expression of GSTA2 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GSTO1 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTP1 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GUCY1A1 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAND2 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAVCR1 mRNA
HDAC1 protein affects the reaction [Hydrocortisone results in decreased expression of CYP11A1 mRNA]; SF1 protein inhibits the reaction [Hydrocortisone results in increased expression of HDAC1 mRNA]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HES5 mRNA
IGF1 protein inhibits the reaction [Hydrocortisone results in decreased expression of HMGCR mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of HMGCR mRNA]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HMOX1 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA1 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA2 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA5 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXB3 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD4 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD8 mRNA
[HSD11B1 protein results in increased metabolism of Ketosteroids] which results in increased chemical synthesis of Hydrocortisone; [HSD11B1 protein results in increased oxidation of Hydrocortisone] which results in increased chemical synthesis of Cortisone; [HSD11B1 protein results in increased reduction of Cortisone] which results in increased chemical synthesis of Hydrocortisone; Dinoprostone promotes the reaction [HSD11B1 protein affects the oxidation of Hydrocortisone]; Hydrocortisone promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA]; Mifepristone affects the reaction [Hydrocortisone affects the expression of HSD11B1 mRNA]; perfluorooctane sulfonic acid inhibits the reaction [Hydrocortisone results in increased expression of HSD11B1] [HSD11B1 protein affects the susceptibility to Hydrocortisone] which results in decreased activity of NFE2L2 protein HSD11B1 protein results in increased chemical synthesis of Hydrocortisone Hydrocortisone results in increased expression of HSD11B1; Hydrocortisone results in increased expression of HSD11B1 mRNA; Hydrocortisone results in increased expression of HSD11B1 protein Hydrocortisone results in increased activity of HSD11B1 protein
HSD11B2 protein binds to Hydrocortisone Hydrocortisone results in decreased expression of HSD11B2 mRNA; Hydrocortisone results in decreased expression of HSD11B2 protein HSD11B2 protein results in increased oxidation of Hydrocortisone [HSD11B2 protein results in increased oxidation of Hydrocortisone] which results in increased chemical synthesis of Cortisone; Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of HSD11B2 mRNA]; Ziram inhibits the reaction [[HSD11B2 protein results in increased oxidation of Hydrocortisone] which results in increased chemical synthesis of Cortisone]; Ziram inhibits the reaction [HSD11B2 protein results in increased oxidation of Hydrocortisone] HSD11B2 protein results in increased metabolism of Hydrocortisone
Hydrocortisone inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]; Hydrocortisone inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Medroxyprogesterone Acetate inhibits the reaction [Hydrocortisone inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]] Hydrocortisone results in decreased expression of ICAM1 protein
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IFI44 mRNA
IFNB1 protein inhibits the reaction [IGF2 protein results in increased secretion of Hydrocortisone]; Mitotane promotes the reaction [IFNB1 protein results in decreased secretion of Hydrocortisone]
[Hydrocortisone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; Hydrocortisone inhibits the reaction [nickel sulfate results in increased secretion of IFNG protein]
IGF1 protein inhibits the reaction [Hydrocortisone results in decreased expression of APOB mRNA]; IGF1 protein inhibits the reaction [Hydrocortisone results in decreased expression of HMGCR mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of IGF1 mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in decreased expression of IGF1 mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in decreased expression of IGF1 protein] Hydrocortisone results in decreased expression of IGF1 mRNA; Hydrocortisone results in decreased expression of IGF1 protein
Hydrocortisone promotes the reaction [Progesterone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IGFBP7 mRNA
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA; Hydrocortisone affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA]
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]
Hydrocortisone results in decreased expression of IL1A mRNA Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]; Hydrocortisone inhibits the reaction [IL1A protein results in increased expression of MMP9 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]]; NR3C1 protein promotes the reaction [Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]]
IL1B protein results in increased abundance of Hydrocortisone Hydrocortisone results in decreased expression of IL1B mRNA Hydrocortisone inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein] [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA; Glycyrrhetinic Acid promotes the reaction [Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]]; Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IL1R1 mRNA
[Hydrocortisone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; Hydrocortisone affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]
Hydrocortisone inhibits the reaction [nickel sulfate results in increased secretion of IL5 protein] Hydrocortisone results in decreased expression of IL5 protein
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA; Octreotide inhibits the reaction [Hydrocortisone results in increased expression of INS protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ISL1 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of KEAP1 mRNA
Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA]; Hydrocortisone inhibits the reaction [[sodium arsenite results in increased abundance of arsenite] which results in decreased expression of KRT1 mRNA]
Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA]; Hydrocortisone inhibits the reaction [[sodium arsenite results in increased abundance of arsenite] which results in decreased expression of KRT10 mRNA]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of LCK mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LEF1 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LUM mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MAFG mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MLIP mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MMP1 mRNA
Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]; Hydrocortisone inhibits the reaction [IL1A protein results in increased expression of MMP9 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]]; NR3C1 protein promotes the reaction [Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MPZL1 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MYL4 mRNA
[Hydrocortisone results in increased activity of NR3C1 protein] inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA [HSD11B1 protein affects the susceptibility to Hydrocortisone] which results in decreased activity of NFE2L2 protein; Hydrocortisone inhibits the reaction [Hydrogen Peroxide promotes the reaction [sulforaphane results in increased expression of NFE2L2 protein]]; Hydrocortisone inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]; Hydrocortisone inhibits the reaction [sulforaphane results in increased expression of NFE2L2 protein]
[Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of NFKBIA mRNA]
Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of NOS2 mRNA]; Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of NOS2 protein]
Hydrocortisone inhibits the reaction [Hydrogen Peroxide promotes the reaction [sulforaphane results in increased expression of NQO1 protein]]; Hydrocortisone inhibits the reaction [sulforaphane results in increased expression of NQO1 mRNA]; Hydrocortisone inhibits the reaction [sulforaphane results in increased expression of NQO1 protein] [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of NQO1 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F1 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F2 mRNA
1,1-bis(4-hydroxyphenyl)cyclohexane inhibits the reaction [Hydrocortisone binds to NR3C1 protein]; 1,1-bis(4-hydroxyphenyl)cyclohexane inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; 2,2',4,4',5-brominated diphenyl ether inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; 3-phenoxybenzoic acid inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; 4,4'-hexafluorisopropylidene diphenol inhibits the reaction [Hydrocortisone binds to NR3C1 protein]; 4,4'-hexafluorisopropylidene diphenol inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; [Hydrocortisone co-treated with Progesterone] results in increased expression of NR3C1 mRNA; [Hydrocortisone results in increased activity of NR3C1 protein] inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]; Atrazine inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; bifenthrin inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; bisphenol A analog inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; bisphenol A inhibits the reaction [Hydrocortisone binds to NR3C1 protein]; bisphenol A inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; bisphenol B inhibits the reaction [Hydrocortisone binds to NR3C1 protein]; bisphenol B inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; croneton inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; cyhalothrin inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; cypermethrin inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; DDT inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; Dichlorodiphenyl Dichloroethylene inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; Hydrocortisone binds to and affects the activity of NR3C1 protein; Hydrocortisone binds to and results in increased activity of NR3C1 protein; Hydrocortisone results in increased expression of and affects the localization of NR3C1 protein; Methoxychlor inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; Mifepristone inhibits the reaction [Hydrocortisone affects the localization of NR3C1 protein]; Mifepristone inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; N-dichlorofluoromethylthio-N',N'-dimethyl-N-p-tolylsulfamide inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; NR3C1 protein affects the reaction [Hydrocortisone results in decreased expression of IGF1 mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in decreased expression of IGF1 protein]; NR3C1 protein affects the reaction [Hydrocortisone results in decreased expression of SIRT1 mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in increased expression of FASN mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in increased expression of SREBF1 mRNA]; NR3C1 protein alternative form inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein alternative form]; NR3C1 protein promotes the reaction [Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]]; o,p'-DDT inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; pentabrominated diphenyl ether 100 inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; Pesticides inhibits the reaction [Hydrocortisone results in increased expression of NR3C1 mRNA]; Polybrominated Biphenyls metabolite inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; resmethrin inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; Soil Pollutants inhibits the reaction [Hydrocortisone results in increased expression of NR3C1 mRNA]; Thiram inhibits the reaction [Hydrocortisone binds to NR3C1 protein]; tributyl phosphate inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; triphenyl phosphate inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; triphenyl phosphate metabolite inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; tris(1,3-dichloro-2-propyl)phosphate inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein] NR3C1 protein binds to Hydrocortisone Hydrocortisone promotes the reaction [[NR3C1 protein binds to TAT promoter] which results in increased expression of TAT mRNA] Hydrocortisone results in increased phosphorylation of NR3C1 protein Hydrocortisone results in decreased expression of NR3C1 mRNA; Hydrocortisone results in decreased expression of NR3C1 protein Fluoxetine promotes the reaction [Hydrocortisone results in increased activity of NR3C1 protein] Hydrocortisone analog binds to NR3C1 protein NR3C1 gene polymorphism affects the abundance of Hydrocortisone Hydrocortisone results in increased expression of NR3C1; Hydrocortisone results in increased expression of NR3C1 mRNA
[Fludrocortisone binds to and results in increased activity of NR3C2 protein] which results in decreased abundance of Hydrocortisone Hydrocortisone results in increased activity of NR3C2 protein
3-phenoxybenzoic acid inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]; bifenthrin inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]; Dactinomycin inhibits the reaction [Hydrocortisone results in increased activity of PCK1 protein]; DDT inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]; Dichlorodiphenyl Dichloroethylene inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]; Methoxychlor inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]; o,p'-DDT inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of PDE1A mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of PLN mRNA
POMC protein results in increased susceptibility to Hydrocortisone Lead inhibits the reaction [POMC protein modified form results in increased secretion of Hydrocortisone]; Melatonin inhibits the reaction [POMC protein results in increased abundance of Hydrocortisone] POMC protein results in increased secretion of Hydrocortisone
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of POU5F1 mRNA
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA]
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA]
[Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] affects the metabolism of 9,10-Dimethyl-1,2-benzanthracene; [Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 protein]; [Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 protein]
Hydrocortisone inhibits the reaction [EGF protein results in increased expression of PTGS2 mRNA] Hydrocortisone results in increased expression of PTGS2 protein Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of PTGS2 protein]
Hydrocortisone results in increased expression of RAP1A mRNA Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of RAP1A mRNA]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RARA mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RBM20 mRNA
Hydrocortisone inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]; Medroxyprogesterone Acetate inhibits the reaction [Hydrocortisone inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RRAD mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SCARB1 mRNA; Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of SCARB1 mRNA]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SEMA3C mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SERPINA1 mRNA
Hydrocortisone results in increased cleavage of and results in increased activity of and affects the localization of SERPINB1A protein modified form Hydrocortisone results in increased cleavage of and results in increased activity of and affects the localization of SERPINB1 protein modified form
Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of SF1 mRNA]; SF1 protein inhibits the reaction [Hydrocortisone results in increased expression of HDAC1 mRNA]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SFRP2 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SH3BP5 mRNA
Hydrocortisone results in decreased expression of SIRT1 mRNA NR3C1 protein affects the reaction [Hydrocortisone results in decreased expression of SIRT1 mRNA]
1-Methyl-3-isobutylxanthine promotes the reaction [[Tretinoin co-treated with Hydrocortisone] affects the localization of SLC5A5 protein]; 1-Methyl-3-isobutylxanthine promotes the reaction [[Tretinoin co-treated with Hydrocortisone] results in increased expression of SLC5A5 protein]; Colforsin inhibits the reaction [[Tretinoin co-treated with Hydrocortisone] results in increased activity of SLC5A5 protein]; Hydrocortisone promotes the reaction [Tretinoin affects the localization of SLC5A5 protein]; Hydrocortisone promotes the reaction [Tretinoin results in increased expression of SLC5A5 protein]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX1 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX2 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SPTSSB mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SQSTM1 mRNA
Hydrocortisone results in increased expression of SREBF1 mRNA [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA; CEBPA protein affects the reaction [Hydrocortisone results in increased expression of SREBF1 mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in increased expression of SREBF1 mRNA]; Resveratrol inhibits the reaction [Hydrocortisone results in increased expression of SREBF1 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SRXN1 mRNA
Hydrocortisone results in decreased expression of STAR mRNA; Hydrocortisone results in decreased expression of STAR protein Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of STAR mRNA]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of STMN2 mRNA
Diethylnitrosamine inhibits the reaction [Hydrocortisone results in increased activity of TAT protein]; o-Aminoazotoluene inhibits the reaction [Hydrocortisone results in increased activity of TAT protein] Hydrocortisone results in increased expression of TAT mRNA beryllium sulfate inhibits the reaction [Hydrocortisone results in increased expression of TAT protein]; cypermethrin inhibits the reaction [Hydrocortisone results in increased expression of TAT mRNA]; Diethylnitrosamine inhibits the reaction [Hydrocortisone results in increased activity of TAT protein]; Hydrocortisone promotes the reaction [[NR3C1 protein binds to TAT promoter] which results in increased expression of TAT mRNA]; Methoxychlor inhibits the reaction [Hydrocortisone results in increased expression of TAT mRNA]; Methyldimethylaminoazobenzene inhibits the reaction [Hydrocortisone results in increased activity of TAT protein]; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of TAT mRNA]; N-dichlorofluoromethylthio-N',N'-dimethyl-N-p-tolylsulfamide inhibits the reaction [Hydrocortisone results in increased expression of TAT mRNA]; o,p'-DDT inhibits the reaction [Hydrocortisone results in increased expression of TAT mRNA]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TBX2 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TF mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2A mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2B mRNA
Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein] [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA
[Hydrocortisone co-treated with sodium arsenate] results in increased expression of TGM1 mRNA; [Hydrocortisone co-treated with sodium arsenite] results in increased expression of TGM1 mRNA; sodium arsenate inhibits the reaction [Hydrocortisone results in increased expression of TGM1 mRNA]; sodium arsenite inhibits the reaction [Hydrocortisone results in increased expression of TGM1 mRNA]
Hydrocortisone results in increased localization of TJP1 protein GGTI 298 inhibits the reaction [Hydrocortisone results in increased localization of TJP1 protein]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TM4SF4 mRNA
Hydrocortisone results in decreased secretion of TNF protein Hydrocortisone affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein]; Hydrocortisone inhibits the reaction [Lipopolysaccharides affects the expression of TNF mRNA]; Hydrocortisone inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Hydrocortisone inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] Hydrocortisone results in decreased expression of TNF mRNA
Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA] 3-phenoxybenzoic acid inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [barium chloride results in increased abundance of Barium] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [cobaltous chloride results in increased abundance of Cobalt] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [cupric chloride results in increased abundance of Copper] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [lead nitrate results in increased abundance of Lead] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [Lithium Chloride results in increased abundance of Lithium] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [stannous chloride results in increased abundance of Tin] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [zinc chloride results in increased abundance of Zinc] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; cyhalothrin inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; DDT inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; Dichlorodiphenyl Dichloroethylene inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; Methoxychlor inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; N-dichlorofluoromethylthio-N',N'-dimethyl-N-p-tolylsulfamide inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; o,p'-DDT inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; resmethrin inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TTR mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TXNRD1 mRNA
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of UGT2A3 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VCAM1 mRNA; Hydrocortisone inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein]; Hydrocortisone inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; Medroxyprogesterone Acetate inhibits the reaction [Hydrocortisone inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein]]
Hydrocortisone inhibits the reaction [Nickel results in increased expression of VEGFA protein] Hydrocortisone results in decreased expression of VEGFA protein
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VGLL1 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ZFAND2A mRNA
browse the term
